Aegros – an Australian clinical-stage biopharmaceutical company and global technology leader in the development and manufacture of plasma-derived medical products (PDMPs), today announced significant changes to its Management Team and Board of Directors.

Mr. Damian Thornton is appointed Chief Executive Officer of Aegros Ltd. Mr. Thornton joined Aegros as CEO, Engineering in January 2022, and has spearheaded the design and establishment of its technologically advanced 125,000 litre Hyperimmune Haemafrac® facility in Macquarie Park, NSW. He brings more than 35 years of experience and expertise in pharmaceutical production facility design and construction, as well as a wealth of executive and commercial leadership experience within the life sciences industry.

Aegros also announces the appointment of Mr. Ray Nolan as Aegros’ new Chairman of the Board of Directors. Mr. Nolan is currently the Chief Executive Officer of the Nolan Group and has been a successful property developer in Australia for more than 40 years.

Mr. James Clyne is appointed Aegros Chief Financial Officer and Company Secretary. Mr Clyne has 15+ years in the finance sector and is supported by two analysts whose experience in financial control and management will ensure a strong ethos of fiscal management.

Aegros has made further changes and expanded its Board of Directors, with 4 new appointments. These additional Non-Executive Directors are Ms. Anne Duggan, Mr. David Burns, Mr. John Clarke and Mr. Max Grundeman. In other changes, the Aegros co-founders Professor Hari Nair and Mr. John Manusu will become Non-Executive Directors. Ms. Janet Bowen also becomes a Non-Executive Director.

These significant changes have been made to support Aegros’ ambition to become a commercial biopharmaceutical company, and global technology partner for the rapidly growing US$30+Bn PDMP industry.